In short
Parkinson's research studies continued. This month's update focused mainly on topics outside Parkinson's research.
Most of the December 2025 update covered other topics. The items about the Parkinson's research are summarized here.
Vika Montano wrote that Zhittya had by then dosed more than 240 people with Parkinson's, five who had had a stroke, two with dementia and two with autism. She said FGF-1 is given as a spray into the nose.
One participant's journey
The update told the story of one participant. When the Parkinson's studies began, it said, the company was reluctant to accept people at more advanced stages. Its priority was people with clear signs of Parkinson's who were not so far along that the body might be unable to respond to FGF-1.
In May 2023 it made an exception for a participant in the later stages. The update shared his own later reports about walking and hand-eye coordination, and linked to a video.
Other participant reports
The update shared further comments from participants and family members. Topics included saliva control, balance, coordination and falls. One came from a participant with progressive supranuclear palsy (PSP), another brain condition, who reported fewer falls and said he still had a long way to go. The update also repeated a family's long account from the month before.
Looking ahead
The brain imaging studies at Washington University in St. Louis were continuing.
In his closing section, Dan Montano, the chief executive, wrote that over the years he had met with participants with stroke, Parkinson's disease and other conditions, and that seeing people do better was what gave the work its meaning for him.
This summary covers the Parkinson's research in the December 2025 update. The complete update, including the other topics it covered, is below.
Read the complete December 2025 update as published
The text of the update Zhittya sent, word for word. Pictures, charts and layout are in the PDF. Open the PDF.